Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 3 4Phase 2 3Phase NA 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 60Breast Neoplasms 22Thyroid Neoplasms 20Neoplasms 20Multiple Endocrine Neoplasia Type 1 20Carcinoma, Renal Cell 20Melanoma 19Carcinoma, Non-Small-Cell Lung 19Adrenocortical Carcinoma 19Small Cell Lung Carcinoma 17Thyroid Cancer, Papillary 16Colorectal Neoplasms 16Thyroid Carcinoma, Anaplastic 15Carcinoma, Neuroendocrine 15Carcinoma, Medullary 14Prostatic Neoplasms 13Pheochromocytoma 13Pancreatic Neoplasms 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Carcinoid Tumor 13Insulinoma 12Uterine Cervical Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Head and Neck Neoplasms 11Adenocarcinoma, Follicular 11Salivary Gland Neoplasms 10Pituitary Neoplasms 10Colonic Neoplasms 10

Interventions

pasireotide 1lanreotide 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Acromegaly × Endocrine × Clear all
NCT05364944 2025-11-17

OXTEND-01

Debiopharm International SA

Phase 1 Terminated
19 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT00446082 2020-12-21

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Novartis

Phase 1 Completed
85 enrolled
Endocrine

Acromegaly, Carcinoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡